Protocol Ledger

NCT06569524 · Phase II · RECRUITING

Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)

Interventional Phase II clinical trial protocol NCT06569524 sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-09-14 Enrollment: 120 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06569524
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)120 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06569524
Protocol FieldVerified Registry Value
NCT IdentifierNCT06569524
Consolidated Lead SponsorChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment120 participants (ESTIMATED)
Registered Start Date2023-09-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06569524
Hospital Research SiteLocationSite Profile
Peking University Shenzhen HospitalShenzhen, ChinaOpen Hospital Dossier ->
Henan Provincial People's HospitalZhengzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI